Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][4] - The company is developing innovative treatments in two therapeutic areas: Medical Dermatology and Respiratory [4] Leadership Change - Peter J. Weiler has been appointed as Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux [1][3] - Mr. Weiler has extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries, previously serving as President of Exzell Pharma, Inc. and in various roles at Cipher Pharmaceuticals Inc. [2][3] Product Pipeline - Edesa's clinical pipeline includes EB06, an anti-CXCL10 monoclonal antibody candidate for vitiligo, and EB01, a Phase 3-ready asset for moderate-to-severe chronic Allergic Contact Dermatitis [4] - The company's advanced respiratory drug candidate, EB05, is being evaluated for Acute Respiratory Distress Syndrome and has received funding from the Government of Canada [4] - Edesa is preparing an investigational new drug application for EB07 to conduct a future Phase 2 study in patients with pulmonary fibrosis [4]
Edesa Biotech Announces Chief Financial Officer Transition